We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Seattle Genetics’ Form 483 Focuses On Recently Approved Cancer Drug
Seattle Genetics’ Form 483 Focuses On Recently Approved Cancer Drug
Seattle Genetics received a six-observation Form 483 from the FDA for documentation and adverse event reporting failures related to its only approved product — cancer drug Adcetris.